Spiramycin
Phase 3Small molecule
Spiramycin is one of 9 small molecule programs targeting Congenital Toxoplasmosis. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in Cryptosporidiosis
#DrugCompanyPhaseTrials
1Spiramycin
RRhone-Poulenc Rorer
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
EDI048
NovartisPhase 2
Cryptosporidium Parvum Oocysts (ABO809)
NovartisPhase 2
Diclazuril
Johnson & JohnsonPreclinical
Interleukin-12
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cryptosporidiosis1 trial
Congenital Toxoplasmosis1 trial
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00004317·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spiramycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRhone-Poulenc Rorer